Why Blackstone’s $250m Anagram deal could reshape pancreatic enzyme therapy
PERT is old, essential and burdensome. Blackstone’s $250m Anagram bet asks whether ANG003 can reset enzyme therapy.
Alcresta’s RELiZORB shows BMI and weight gains in pediatric tube-fed patients
See how RELiZORB improved weight and BMI z-scores in tube-fed children aged 1–5 in new real-world data. Explore what this means for pediatric care today.
Can Clarametyx’s CMTX-101 reshape cystic fibrosis care by targeting biofilms?
Clarametyx’s CMTX-101 showed strong early signals in cystic fibrosis. Find out what this means for chronic lung infections and future bronchiectasis care.